PAM
PBYI icon

Paradigm Asset Management’s Puma Biotechnology PBYI Stock Holding History

Paradigm Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,300
Closed -$310K – 816
2014
Q3 		$310K Buy
+1,300
New +$267K 0.04% 412

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Asset Management's PBYI Position: Q4 2014 in Review

Paradigm Asset Management sold out of Puma Biotechnology (PBYI) in Q4 2014, closing a stake of 1,300 shares — an estimated $310K sold.

Paradigm Asset Management first reported a position in PBYI in Q3 2014 and held it in 1 quarter. The position peaked at $310K in Q3 2014. 188 funds tracked by Wall St. Rank hold PBYI as of Q4 2014.

  • Paradigm Asset Management reported no remaining Puma Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Paradigm Asset Management sold 1,300 Puma Biotechnology shares in Q4 2014, an estimated $310K.
  • Paradigm Asset Management first reported a position in Puma Biotechnology in Q3 2014 and held it in 1 quarter.
  • Paradigm Asset Management's Puma Biotechnology position peaked at $310K in Q3 2014.
  • 188 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2014.

Based on Paradigm Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.